NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Galzus Research,

Did JANX have an inclusion criteria that needed to be reworked since folks were not having opportunity for the treatment to work?; ). Trying to generalize about Phase 1 trials in this case is not justifiable. This Direct trial was deliberately hampered by first in man designation which included spacing of treatments that was not optimized, two different maturation stages and three different cell count dosing levels. Safety proved out and life changing results occurred because the science played out as expected. The results were exceptional for a Phase 1 considering all the limitations. Best wishes.